This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Concert Pharmaceuticals 미래 성장
Future 기준 확인 2/6
주요 정보
38.9%
수익 성장률
43.3%
EPS 성장률
| Biotechs 수익 성장 | 24.1% |
| 매출 성장률 | 54.9% |
| 향후 자기자본 수익 률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 06 Mar 2023 |
최근 미래 성장 업데이트
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2025 | 96 | -69 | N/A | -86 | 2 |
| 12/31/2024 | 29 | -129 | N/A | -140 | 2 |
| 12/31/2023 | 18 | -137 | N/A | -78 | 3 |
| 12/31/2022 | 0 | -122 | N/A | N/A | 3 |
| 9/30/2022 | 32 | -127 | -110 | -110 | N/A |
| 6/30/2022 | 33 | -125 | -103 | -102 | N/A |
| 3/31/2022 | 33 | -95 | -67 | -67 | N/A |
| 12/31/2021 | 33 | -80 | -55 | -55 | N/A |
| 9/30/2021 | 1 | -66 | -45 | -45 | N/A |
| 6/30/2021 | 2 | -59 | -47 | -47 | N/A |
| 3/31/2021 | 8 | -77 | -72 | -72 | N/A |
| 12/31/2020 | 8 | -75 | -69 | -69 | N/A |
| 9/30/2020 | 8 | -73 | -68 | -68 | N/A |
| 6/30/2020 | 6 | -71 | -64 | -63 | N/A |
| 3/31/2020 | 0 | -77 | -66 | -65 | N/A |
| 12/31/2019 | 1 | -78 | -49 | -49 | N/A |
| 9/30/2019 | 1 | -79 | -50 | -49 | N/A |
| 6/30/2019 | 1 | -79 | -47 | -45 | N/A |
| 3/31/2019 | 1 | -73 | -40 | -37 | N/A |
| 12/31/2018 | 11 | -56 | -51 | -48 | N/A |
| 9/30/2018 | 11 | -41 | -41 | -39 | N/A |
| 6/30/2018 | 11 | 104 | 104 | 106 | N/A |
| 3/31/2018 | 11 | 104 | 104 | 105 | N/A |
| 12/31/2017 | 0 | 95 | 103 | 104 | N/A |
| 9/30/2017 | 0 | 89 | 98 | 99 | N/A |
| 6/30/2017 | 0 | -50 | -46 | -45 | N/A |
| 3/31/2017 | 0 | -50 | -45 | -44 | N/A |
| 12/31/2016 | 0 | -51 | -46 | -45 | N/A |
| 9/30/2016 | 10 | -38 | -33 | -33 | N/A |
| 6/30/2016 | 12 | -35 | N/A | -30 | N/A |
| 3/31/2016 | 15 | 19 | N/A | 20 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: CNCE is forecast to remain unprofitable over the next 3 years.
수익 vs 시장: CNCE is forecast to remain unprofitable over the next 3 years.
고성장 수익: CNCE is forecast to remain unprofitable over the next 3 years.
수익 대 시장: CNCE's revenue (54.9% per year) is forecast to grow faster than the US market (7% per year).
고성장 수익: CNCE's revenue (54.9% per year) is forecast to grow faster than 20% per year.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: Insufficient data to determine if CNCE's Return on Equity is forecast to be high in 3 years time